Get the latest tech news

Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

None

Related news:

Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma

Moderna, Merck Vaccine Succeeds in Preventing Melanoma From Returning

Stanford is running 37,000 AI agents as a virtual biotech — and one of its drug designs got independently confirmed by Merck